中华实验和临床感染病杂志（电子版）
中華實驗和臨床感染病雜誌（電子版）
중화실험화림상감염병잡지（전자판）
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL INFECTIOUS DISEASES(ELECTRONIC VERSION)
2014年
6期
796-799
,共4页
李文利%钮自宇%张鸣鸣%李林浩%滕春媛%战淑慧
李文利%鈕自宇%張鳴鳴%李林浩%滕春媛%戰淑慧
리문리%뉴자우%장명명%리림호%등춘원%전숙혜
大蒜素%慢性萎缩性胃炎%表皮生长因子(EGF)%表皮生长因子受体(EGFR)
大蒜素%慢性萎縮性胃炎%錶皮生長因子(EGF)%錶皮生長因子受體(EGFR)
대산소%만성위축성위염%표피생장인자(EGF)%표피생장인자수체(EGFR)
Allicin%Atrophic gastritis%Epidermal growth factor (EGF)%Epidermal growth factor receptor (EGFR)
目的：观察大蒜素对幽门螺杆菌（Hp）阴性慢性萎缩性胃炎（CAG）患者血清表皮生长因子（EGF）及胃黏膜病理、表皮生长因子受体（EGFR）表达水平的影响。方法采用随机对照方法，将Hp阴性慢性萎缩性胃炎患者120例随机分为治疗组和空白对照组，其中治疗组60例患者给予大蒜素治疗，对照组60例患者给予与大蒜素剂型相同的安慰剂；疗程为24周，治疗前后两组患者均进行血清EGF、胃黏膜EGFR表达以及病理积分比较。结果治疗组患者大蒜素治疗后EGF、EGFR表达水平以及病理积分较治疗前降低，差异有统计学意义（P均＜0.05）；对照组患者治疗前后EGF、EGFR表达水平以及病理积分差异无统计学意义（P均＞0.05）。结论大蒜素对慢性萎缩性胃炎的病理积分有改善作用，且能够降低萎缩性胃炎EGF及EGFR的表达水平，这可能是其发挥作用的机制之一。
目的：觀察大蒜素對幽門螺桿菌（Hp）陰性慢性萎縮性胃炎（CAG）患者血清錶皮生長因子（EGF）及胃黏膜病理、錶皮生長因子受體（EGFR）錶達水平的影響。方法採用隨機對照方法，將Hp陰性慢性萎縮性胃炎患者120例隨機分為治療組和空白對照組，其中治療組60例患者給予大蒜素治療，對照組60例患者給予與大蒜素劑型相同的安慰劑；療程為24週，治療前後兩組患者均進行血清EGF、胃黏膜EGFR錶達以及病理積分比較。結果治療組患者大蒜素治療後EGF、EGFR錶達水平以及病理積分較治療前降低，差異有統計學意義（P均＜0.05）；對照組患者治療前後EGF、EGFR錶達水平以及病理積分差異無統計學意義（P均＞0.05）。結論大蒜素對慢性萎縮性胃炎的病理積分有改善作用，且能夠降低萎縮性胃炎EGF及EGFR的錶達水平，這可能是其髮揮作用的機製之一。
목적：관찰대산소대유문라간균（Hp）음성만성위축성위염（CAG）환자혈청표피생장인자（EGF）급위점막병리、표피생장인자수체（EGFR）표체수평적영향。방법채용수궤대조방법，장Hp음성만성위축성위염환자120례수궤분위치료조화공백대조조，기중치료조60례환자급여대산소치료，대조조60례환자급여여대산소제형상동적안위제；료정위24주，치료전후량조환자균진행혈청EGF、위점막EGFR표체이급병리적분비교。결과치료조환자대산소치료후EGF、EGFR표체수평이급병리적분교치료전강저，차이유통계학의의（P균＜0.05）；대조조환자치료전후EGF、EGFR표체수평이급병리적분차이무통계학의의（P균＞0.05）。결론대산소대만성위축성위염적병리적분유개선작용，차능구강저위축성위염EGF급EGFR적표체수평，저가능시기발휘작용적궤제지일。
Objective To explore the inlfuences of allicin on serum epidermal growth factor (EGF), gastric mucosa epidermal growth factor receptor (EGFR) expression and pathological points of chronic atrophic gastritis (CAG) without Helicobacter pylori (Hp) infection. Methods Total of 120 patients with Hp negative CAG diagnosed by the gastroscopy and pathological examination were investigated by randomized control method in Qingdao Municipal Hospital. They all were randomly divided into treatment group and control group, with 60 cases in each group. Patients in treatment group were given allicin while patients in control group were given placebo. The period of treatment for the two groups were 24 weeks. The ifndings of gastroscopy and histology of gastric mucosa, as well as the serum EGF and gastritis mucosa EGFR were recorded and compared before and after the treatment, respectively. Results After therapy, EGF, EGFR expression and pathological points were lower than before in treatment group, with signiifcant differences (P all<0.05);while that in the control group was not with signiifcant difference (P all>0.05). Conclusions Allicin could improve chronic atrophic gastritis pathological points and signiifcantly improve the pathological situation, and reduce the levels of serum EGF and gastric mucosa EGFR expression, which may be one of the mechanisms of allicin improving pathological points for the Hp-negative CAG.
